PL3294270T3 - Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta - Google Patents

Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta

Info

Publication number
PL3294270T3
PL3294270T3 PL17712970T PL17712970T PL3294270T3 PL 3294270 T3 PL3294270 T3 PL 3294270T3 PL 17712970 T PL17712970 T PL 17712970T PL 17712970 T PL17712970 T PL 17712970T PL 3294270 T3 PL3294270 T3 PL 3294270T3
Authority
PL
Poland
Prior art keywords
delta
pharmaceutical composition
composition containing
containing rifaximin
rifaximin alpha
Prior art date
Application number
PL17712970T
Other languages
English (en)
Inventor
Johannes Raneburger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55637248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3294270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of PL3294270T3 publication Critical patent/PL3294270T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL17712970T 2016-03-24 2017-03-22 Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta PL3294270T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16162415 2016-03-24
PCT/EP2017/056797 WO2017162725A1 (en) 2016-03-24 2017-03-22 Pharmaceutical composition containing rifaximin alpha & delta
EP17712970.7A EP3294270B1 (en) 2016-03-24 2017-03-22 Pharmaceutical composition containing rifaximin alpha&delta

Publications (1)

Publication Number Publication Date
PL3294270T3 true PL3294270T3 (pl) 2019-02-28

Family

ID=55637248

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18193241T PL3434265T3 (pl) 2016-03-24 2017-03-22 Kompozycja farmaceutyczna zawierająca rifaksyminę alfa i delta
PL17712970T PL3294270T3 (pl) 2016-03-24 2017-03-22 Farmaceutyczna kompozycja zawierająca rifaksyminę alfa i delta

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18193241T PL3434265T3 (pl) 2016-03-24 2017-03-22 Kompozycja farmaceutyczna zawierająca rifaksyminę alfa i delta

Country Status (7)

Country Link
US (1) US10576065B2 (pl)
EP (2) EP3434265B1 (pl)
ES (2) ES2893869T3 (pl)
HU (2) HUE040253T2 (pl)
PL (2) PL3434265T3 (pl)
TR (1) TR201816080T4 (pl)
WO (1) WO2017162725A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
EP3143027B1 (en) 2014-05-12 2019-07-10 Alfasigma S.p.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
ES2893869T3 (es) 2016-03-24 2022-02-10 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9085507B2 (en) * 2009-05-11 2015-07-21 Ratiopharm Gmbh Desfesoterodine in the form of a tartaric acid salt
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9018225B1 (en) * 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
ES2893869T3 (es) 2016-03-24 2022-02-10 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta

Also Published As

Publication number Publication date
ES2700423T3 (es) 2019-02-15
EP3294270B1 (en) 2018-09-12
EP3434265A1 (en) 2019-01-30
PL3434265T3 (pl) 2021-12-13
EP3294270A1 (en) 2018-03-21
EP3434265B1 (en) 2021-07-07
WO2017162725A1 (en) 2017-09-28
US10576065B2 (en) 2020-03-03
HUE040253T2 (hu) 2019-02-28
HUE056045T2 (hu) 2022-01-28
TR201816080T4 (tr) 2018-11-21
ES2893869T3 (es) 2022-02-10
US20180169076A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
IL265260B (en) pharmaceutical preparations
IL265360A (en) Pharmaceutical composition
IL262654A (en) Pharmacy preparation
IL267224A (en) Pharmaceutical preparations containing insulin
PT3421038T (pt) Compostos de naftiridina, combinações médicas e sua utilização
IL265349A (en) Pharmaceutical composition
SI3278801T1 (sl) Farmacevtski sestavek, ki vsebuje mirabegron
IL263040A (en) Pharmaceutical composition comprising eteplirsen
PL3454838T3 (pl) Kompozycja farmaceutyczna
HUE044432T2 (hu) Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
HUE056045T2 (hu) Rifaximin alfa és delta tartalmú gyógyászati készítmény
GB201615917D0 (en) Pharmaceutical composition
IL267136A (en) Pharmaceutical composition containing celecoxib
IL266825A (en) Pharmaceutical formulation containing tadalafil
GB201615914D0 (en) Pharmaceutical composition
IL271513A (en) Innovative pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
ZA201902767B (en) Pharmaceutical compositions comprising rifaximin
IL265436B (en) Pharmacy preparation
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201620519D0 (en) Pharmaceutical composition
IL265428A (en) Pharmaceutical composition
ZA201806445B (en) Antiperspirant composition
PL3329939T3 (pl) Stała kompozycja farmaceutyczna nienadająca się do nadużywania
PT3476391T (pt) Composição farmacêutica que compreende arginina para utilização no tratamento da doença de poliq